PuSH - Publikationsserver des Helmholtz Zentrums München

Jia, J. ; Trassl, L. ; Kong, F.* ; Deng, B. ; Liu, R.* ; Sun, Z.* ; Lan, X.* ; Yildirim, A.Ö. ; Stathopoulos, G.T. ; Fernandez, I.E. ; Schamberger, A.C.

Improved survival of patients with stage III small-cell lung cancer with primary resection: A SEER-based analysis.

Transl. Oncol. 49:102070 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
INTRODUCTION: Small cell lung cancer (SCLC) is mostly diagnosed in stage III-IV patients and associated with poor prognosis. To date, surgery is no gold-standard treatment for any SCLC stage and evidence is lacking whether it is beneficial. Here we investigate the impact of surgery, with special attention to stage III SCLC patients, sub-stages and treatment combinations. METHODS: The overall survival (OS) and cancer-specific survival (CSS) of 33,198 SCLC patients (SEER database) were analyzed retrospectively, using various statistical analyses, including propensity score matching (PSM), recursive partitioning, and sequential landmark analyses. RESULTS: Independent of stage, the OS of patients with surgery-including treatments was almost always better than without surgery. This holds true for stage I-II patients, even after PMS analysis (p < 0.017). The same was found for stage IV patients that underwent surgery plus chemotherapy vs. chemotherapy alone (p = 0.013 after PSM). Stage III patients showed a robust improvement in OS and CSS after surgery (OS: 18 vs.13 months) or surgery plus chemotherapy (OS: 20 vs.15 months) as confirmed by well-balanced PSM and sequential landmark analyses of long-term survivors. More detailed analyses using two independent approaches showed prolonged OS in T3-4/N0-1 and T1-2/N2 stage III patients after surgery or surgery plus chemotherapy. Importantly, primary site surgery had a major survival advantage over surgery at regional sites (p < 0.003). CONCLUSION: Our study demonstrates that selected patients of all stages, including stage III T3-4/N0-1 and T1-2/N2, can benefit greatly from surgery-including treatments. Thus, surgery should be included into hospital treatment recommendations for specifically selected SCLC patients. Condensed abstract Primary resection in patients with stage III SCLC needs re-evaluation. Selected patients with stage III SCLC benefit significantly from surgery. Patients with T3-4/N0-1 and T1-2/N2 stage III SCLC should be considered for surgery.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter And End Results (seer), Surgery, Outcome ; Epidemiology ; Small Cell Lung Cancer ; Surveillance; Surgical Resection; Nonsurgical Management; Surgery; Chemotherapy; Trial; Radiotherapy; Lobectomy; Carcinoma; Diagnosis; Therapy
e-ISSN 1936-5233
Zeitschrift Translational Oncology
Quellenangaben Band: 49, Heft: , Seiten: , Artikelnummer: 102070 Supplement: ,
Verlag Neoplasia Press
Verlagsort Ste 800, 230 Park Ave, New York, Ny 10169 Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Lung Health and Immunity (LHI)
Institute of Lung Biology (LHI)
Förderungen Helmholtz Munich
German Center for Lung Research
Ludwig-Maximilians-Universitat Muenchen
Deutsche Forschungsgemeinschaft (DFG)